Published in Ann Oncol on May 01, 2010
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol (2014) 4.54
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol (2013) 1.99
Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol (2011) 1.43
Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol (2014) 1.13
Bone matters in lung cancer. Ann Oncol (2012) 1.08
Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol (2011) 1.00
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Ann Oncol (2011) 0.97
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol (2013) 0.96
Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther (2012) 0.96
Overexpression of microRNA-95-3p suppresses brain metastasis of lung adenocarcinoma through downregulation of cyclin D1. Oncotarget (2015) 0.94
Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer (2011) 0.92
Estimating quality adjusted progression free survival of first-line treatments for EGFR mutation positive non small cell lung cancer patients in The Netherlands. Health Qual Life Outcomes (2012) 0.92
Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: A systematic review. Ann Thorac Med (2013) 0.92
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe. Clinicoecon Outcomes Res (2012) 0.91
Secretomic analysis identifies alpha-1 antitrypsin (A1AT) as a required protein in cancer cell migration, invasion, and pericellular fibronectin assembly for facilitating lung colonization of lung adenocarcinoma cells. Mol Cell Proteomics (2012) 0.89
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis. BMC Cancer (2013) 0.88
A Five-miRNA Panel Identified From a Multicentric Case-control Study Serves as a Novel Diagnostic Tool for Ethnically Diverse Non-small-cell Lung Cancer Patients. EBioMedicine (2015) 0.88
Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment. Cancer Manag Res (2013) 0.88
Bone metastases: When and how lung cancer interacts with bone. World J Clin Oncol (2014) 0.87
Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. J Thorac Dis (2015) 0.87
Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol (2011) 0.87
miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein. Oncotarget (2016) 0.86
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. Clinicoecon Outcomes Res (2012) 0.85
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther (2013) 0.85
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group. Br J Cancer (2012) 0.84
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents. J Cancer Res Clin Oncol (2012) 0.84
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol (2016) 0.84
Chest wall tumors: Diagnosis, treatment and reconstruction. Exp Ther Med (2015) 0.83
Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer (2012) 0.83
Suitability of surgical tumor tissues, biopsy, or cytology samples for epidermal growth factor receptor mutation testing in non-small cell lung carcinoma based on chinese population. Transl Oncol (2014) 0.83
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). Br J Cancer (2012) 0.82
Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. Curr Oncol (2014) 0.81
Prognostic role of the ABO blood types in Chinese patients with curatively resected non-small cell lung cancer: a retrospective analysis of 1601 cases at a single cancer center. Chin J Cancer (2015) 0.81
Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget (2016) 0.80
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. J Biomol Screen (2016) 0.79
Functional imaging in lung cancer. Clin Physiol Funct Imaging (2013) 0.78
Chemotherapy of lung cancer: A global perspective of the role of ifosfamide. Transl Lung Cancer Res (2012) 0.78
Influence of Preoperative Serum Aspartate Aminotransferase (AST) Level on the Prognosis of Patients with Non-Small Cell Lung Cancer. Int J Mol Sci (2016) 0.78
Comorbidity and survival of Danish lung cancer patients from 2000-2011: a population-based cohort study. Clin Epidemiol (2013) 0.77
Ubiquitin-specific protease 4 controls metastatic potential through β-catenin stabilization in brain metastatic lung adenocarcinoma. Sci Rep (2016) 0.77
Quality indicators for the evaluation of patients with lung cancer. Chest (2014) 0.76
Microeconomic surplus in health care: applied economic theory in health care in four European countries. Front Pharmacol (2013) 0.76
Survival in patients with synchronous liver metastases in central and northern Denmark, 1998 to 2009. Clin Epidemiol (2011) 0.76
Reduced folate carrier (RFC) as a predictive marker for response to pemetrexed in advanced non-small cell lung cancer (NSCLC). Invest New Drugs (2013) 0.76
Increased Wnt5a in squamous cell lung carcinoma inhibits endothelial cell motility. BMC Cancer (2016) 0.75
The role of microRNA-21 in predicting brain metastases from non-small cell lung cancer. Onco Targets Ther (2016) 0.75
MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer. Neuro Oncol (2016) 0.75
The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer. Diagnostics (Basel) (2016) 0.75
Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer Cell Int (2015) 0.75
The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials. Onco Targets Ther (2016) 0.75
Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design. Health Qual Life Outcomes (2013) 0.75
Improving Spiritual Well-Being in Patients with Lung Cancers. J Pastoral Care Counsel (2015) 0.75
Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in Turkey. Springerplus (2016) 0.75
Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions. J Transl Med (2017) 0.75
Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy. Radiol Oncol (2016) 0.75
Transcriptional factor FOXO3 negatively regulates the expression of nm23-H1 in non-small cell lung cancer. Thorac Cancer (2015) 0.75
The RET fusion gene and its correlation with demographic and clinicopathological features of non-small cell lung cancer: a meta-analysis. Cancer Biol Ther (2015) 0.75
Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review). Int J Oncol (2015) 0.75
Anti-tumor effect of cactus polysaccharides on lung squamous carcinoma cells (SK-MES-1). Afr J Tradit Complement Altern Med (2014) 0.75
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respir Med Case Rep (2016) 0.75
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials. Int J Clin Oncol (2012) 0.75
Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy. Int J Clin Oncol (2016) 0.75
Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients. PLoS One (2017) 0.75
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. Br J Cancer (2017) 0.75
Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience. Support Care Cancer (2015) 0.75
Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction. Mol Diagn Ther (2017) 0.75
A study of the Moraxella group. II. Oxidative-negative species (genus Acinetobacter). J Bacteriol (1968) 7.77
Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J (2009) 6.64
Taxonomy of marine bacteria: the genus Beneckea. J Bacteriol (1971) 6.47
Study of genetic relationships among marine species of the genera Beneckea and Photobacterium by means of in vitro DNA/DNA hybridization. Arch Microbiol (1976) 4.15
Isolation of Acinetobacter from soil and water. J Bacteriol (1968) 4.12
Study of the Moraxella group. I. Genus Moraxella and the Neisseria catarrhalis group. J Bacteriol (1968) 3.78
Pea aphid symbiont relationships established by analysis of 16S rRNAs. J Bacteriol (1989) 3.73
Biology of the marine enterobacteria: genera Beneckea and Photobacterium. Annu Rev Microbiol (1977) 3.65
Synergistic actions of Rad51 and Rad52 in recombination and DNA repair. Nature (1998) 3.57
Evidence for the establishment of aphid-eubacterium endosymbiosis in an ancestor of four aphid families. J Bacteriol (1991) 3.35
Taxonomy of aerobic marine eubacteria. J Bacteriol (1972) 3.09
The TATA-binding protein: a general transcription factor in eukaryotes and archaebacteria. Science (1994) 3.06
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 3.06
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 3.03
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry (1998) 2.96
Structure and arrangement of flagella in species of the genus Beneckea and Photobacterium fischeri. J Bacteriol (1971) 2.93
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 2.80
Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.77
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.75
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 2.67
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.63
Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol (2010) 2.54
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 2.53
Taxonomy of marine bacteria: Beneckea parahaemolytica and Beneckea alginolytica. J Bacteriol (1973) 2.52
Purification of the larvicidal toxin of Bacillus sphaericus and evidence for high-molecular-weight precursors. J Bacteriol (1985) 2.51
Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J (2010) 2.51
Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol (2012) 2.38
Incisional hernia rate 3 years after midline laparotomy. Br J Surg (2013) 2.37
A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol (1999) 2.32
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.31
Bacterial endosymbionts in animals. Curr Opin Microbiol (2000) 2.25
Amplification of trpEG: adaptation of Buchnera aphidicola to an endosymbiotic association with aphids. Proc Natl Acad Sci U S A (1994) 2.20
Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol (2010) 2.19
Cospeciation of psyllids and their primary prokaryotic endosymbionts. Appl Environ Microbiol (2000) 2.15
High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.08
Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 2.07
Sequence evolution in bacterial endosymbionts having extreme base compositions. Mol Biol Evol (1999) 2.07
Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 2.06
Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol (2012) 2.04
The effect of aortic valve replacement on survival. Circulation (1982) 2.03
Effect of sodium chloride on growth of heterotrophic marine bacteria. Arch Microbiol (1974) 1.99
Phylogenetics of cytoplasmically inherited microorganisms of arthropods. Trends Ecol Evol (1994) 1.98
Cospeciation between bacterial endosymbionts (Buchnera) and a recent radiation of aphids (Uroleucon) and pitfalls of testing for phylogenetic congruence. Evolution (2000) 1.97
Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J (2008) 1.97
Pathways of D-fructose catabolism in species of Pseudomonas. Arch Microbiol (1977) 1.93
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2014) 1.93
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol (2007) 1.90
Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.87
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.84
Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol (2012) 1.80
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol (2012) 1.79
Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.79
Sequence analysis of the mosquitocidal toxin genes encoding 51.4- and 41.9-kilodalton proteins from Bacillus sphaericus 2362 and 2297. J Bacteriol (1988) 1.75
Two years of Finnish Telestroke: thrombolysis at spokes equal to that at the hub. Neurology (2011) 1.75
Phylogenetic relationships of the endosymbionts of mealybugs (Homoptera: Pseudococcidae) based on 16S rDNA sequences. Mol Phylogenet Evol (1992) 1.73
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.73
Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.72
Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.70
Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol (2010) 1.69
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.67
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer. Ann Oncol (2010) 1.63
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.63
Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.61
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.60
Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J (2008) 1.58
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.57
Cloning and sequencing of the gene encoding a 125-kilodalton surface-layer protein from Bacillus sphaericus 2362 and of a related cryptic gene. J Bacteriol (1989) 1.56
Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol (2010) 1.55
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.54
Isolation, enumeration, and host range of marine Bdellovibrios. Arch Microbiol (1974) 1.53
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.52
Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.52
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol (2010) 1.51
Catabolism of D-fructose and D-ribose by Pseudomonas doudoroffii. I. Physiological studies and mutant analysis. Arch Microbiol (1975) 1.51
Rupture and dissection in pulmonary artery aneurysms: incidence, cause, and treatment--review and case report. J Thorac Cardiovasc Surg (2001) 1.49
A comparative study of the diagnostic performance of amniotic fluid glucose, white blood cell count, interleukin-6, and gram stain in the detection of microbial invasion in patients with preterm premature rupture of membranes. Am J Obstet Gynecol (1993) 1.49
Evolutionary relationships in vibrio and Photobacterium: a basis for a natural classification. Annu Rev Microbiol (1983) 1.49
Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.48
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.48
Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 1.48
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.47
Bone health in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol (2014) 1.46
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. Ann Oncol (2013) 1.46
Inappropriate secretion of antidiuretic hormone and SSRIs. Br J Psychiatry (1996) 1.46
Precise binding of single-stranded DNA termini by human RAD52 protein. EMBO J (2000) 1.46
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.46
Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.44
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 1.43
Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 1.43
Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 1.42